Mostrar o rexistro simple do ítem

dc.contributor.authorCordero Santamaría, Óscar Javier
dc.contributor.authorViéitez González, Irene
dc.contributor.authorAltabás González, Irene
dc.contributor.authorNuño Nuño, Laura
dc.contributor.authorVillalba Yllán, Alejandro
dc.contributor.authorNovella Navarro , Marta
dc.contributor.authorPeiteado López, Diana
dc.contributor.authorMiranda-Carús, María-Eugenia
dc.contributor.authorBalsa Criado, Alejandro
dc.contributor.authorVarela Calviño, Rubén
dc.contributor.authorGómez Touriño, Iria María
dc.contributor.authorPego Reigosa, José María
dc.date.accessioned2022-08-29T08:36:15Z
dc.date.available2022-08-29T08:36:15Z
dc.date.issued2022
dc.identifier.citationArchivum Immunologiae et Therapiae Experimentalis 70, 12 (2022). https://doi.org/10.1007/s00005-022-00649-6
dc.identifier.issn0004-069X
dc.identifier.urihttp://hdl.handle.net/10347/29165
dc.description.abstractIn rheumatoid arthritis (RA), the identifcation of biomarkers to adjust treatment intensity and to correctly diagnose the disease in early stages still constitutes a challenge and, as such, novel biomarkers are needed. We proposed that autoantibodies (aAbs) against CD26 (DPP4) might have both etiological importance and clinical value. Here, we perform a prospective study of the potential diagnostic power of Anti-CD26 aAbs through their quantifcation in plasmas from 106 treatment-naïve early and undiferentiated AR. Clinical antibodies, Anti-CD26 aAbs, and other disease-related biomarkers were measured in plasmas obtained in the frst visit from patients, which were later classifed as RA and non-RA according to the American College of Rheumatology criteria. Two diferent isotype signatures were found among ten groups of patients, one for AntiCD26 IgA and other for Anti-CD26 IgG and IgM isotypes, both converging in patients with arthritis (RA and Unresolved Undiferentiated Arthritis: UUA), who present elevated levels of all three isotypes. The four UUA patients, unresolved after two years, were ACPA and rheumatic factor (RF) negatives. In the whole cohort, 51.3% of ACPA/RF seronegatives were Anti-CD26 positives, and a similar frequency was observed in the seropositive RA patients. Only weak associations of the three isotypes with ESR, CRP and disease activity parameters were observed. Anti-CD26 aAbs are present in treatmentnaïve early arthritis patients, including ACPA and RF seronegative individuals, suggestive of a potential pathogenic and/or biomarker role of Anti-CD26 aAbs in the development of rheumatic diseases
dc.description.sponsorshipOpen Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the European Union (Interreg V-A Spain-Portugal Cooperative Program (POCTEP), the Health Research Institute Carlos III (ISCIII/PI21/00370/Cofinanciado por la Unión Europea/FEDER), and 0227_CodigoMais_1_E, USC-SERGAS Cooperation 2018–2019
dc.language.isoeng
dc.publisherSpringer
dc.rights© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ Atribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAutoantibodies
dc.subjectCD26
dc.subjectAnti-CD26
dc.subjectEarly rheumatoid arthritis
dc.subjectAutoimmunity
dc.subjectEtiology
dc.titleStudy of plasma anti-CD26 autoantibody levels in a cohort of treatment-naïve early arthritis patients
dc.typejournal article
dc.identifier.doi10.1007/s00005-022-00649-6
dc.relation.publisherversionhttps://doi.org/10.1007/s00005-022-00649-6
dc.type.hasVersionVoR
dc.identifier.essn1661-4917
dc.rights.accessRightsopen access
dc.contributor.affiliationUniversidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicas
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Bioquímica e Bioloxía Molecular
dc.description.peerreviewedSI


Ficheiros no ítem

application/pdf
Nome: 2022_archimm_cordero_study.pdf
Tamaño: 1.198 Mb
Formato: PDF


Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ Atribución 4.0 Internacional
A licenza do ítem descríbese como
 © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ Atribución 4.0 Internacional





Recolectores:Enlaces de interese:
Universidade de Santiago de Compostela | Teléfonos: +34 881 811 000 e +34 982 820 000 | Contacto | Suxestións